13 enrolling by invitation. 13 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Enrolling by invitation 13 |
| Phase 3 | 4 | Enrolling by invitation 4 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Enrolling by invitation | Bnai Zion Medical Center | 12 | 2026-06-01 | 2026-07-08 |
| Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 55 | 2026-04-13 | 2026-10-05 |
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). HVA - Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 40 | 2026-04-01 | 2026-04-08 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
| RVU120 Rollover Study RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Enrolling by invitation | Ryvu Therapeutics SA | 14 | 2025-12-04 | 2026-09-17 |
| Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum - Probiotics, Gastrointestinal Diseases | Phase 2 | Enrolling by invitation | National Institute of Pediatrics, Mexico | 120 | 2025-02-01 | 2025-03-14 |
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients venetoclax - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 98 | 2023-08-01 | 2024-08-09 |
| Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions - Acute Myeloid Leukemia | Phase 2 | Enrolling by invitation | Michael Pulsipher | 30 | 2021-08-24 | 2025-05-04 |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) ASTX727 - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Enrolling by invitation | Taiho Oncology, Inc. | 332 | 2019-09-30 | 2026-07-28 |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children CliniMacs TCR alpha-beta-Biotin system - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Enrolling by invitation | Michael Pulsipher | 50 | 2015-10-01 | 2025-05-04 |
Leukemia, Myeloid, Acute (8) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Neoplasm, Residual (2) · Gastrointestinal Diseases (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Promyelocytic, Acute (1) · Neoplasm Metastasis (1) · Recurrence (1)
Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Leukemia, Myeloid (9) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Leukemia, Lymphoid (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bone Marrow Diseases (3) · Neoplastic Processes (3)
Azacitidine (2) · Induction Chemotherapy (2) · Opiate Substitution Treatment (2) · Cytarabine (1) · Homoharringtonine (1) · Lisaftoclax (1) · Maintenance (1) · decitabine and cedazuridine drug combination (1) · ruxolitinib (1) · venetoclax (1) · zanubrutinib (1)
Guangdong Second Provincial General Hospital (3) · First Affiliated Hospital of Zhejiang University (2) · Michael Pulsipher (2) · Bnai Zion Medical Center (1) · National Institute of Pediatrics, Mexico (1) · Ryvu Therapeutics SA (1) · SWOG Cancer Research Network (1) · Taiho Oncology, Inc. (1) · The First Affiliated Hospital of Soochow University (1)
China (6) · United States (4) · France (2) · Poland (2) · Armenia (1) · Austria (1) · Bulgaria (1) · Canada (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Mexico (1) · Romania (1) · Slovakia (1)
Anjali S Advani (1) · Guopan Yu, PhD (1) · Michael L Pulsipher, MD (1) · Michael Pulsipher, MD (1) · Sara Espinosa-Padilla, Ph.D. (1)
PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 25040088, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 35776909, PMID 39042892, PMID 9718381
2018 (1), 2025 (1)